Skip to search formSkip to main contentSkip to account menu

Cardioxane

Known as: Cardioxan 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Dexrazoxane

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
Comparative open, randomized, cross-over bioequivalence study of two intravenous dexrazoxane formulations (Cardioxane® and ICRF-187) in patients with advanced breast cancer, treated with 5…
SummaryThe purpose of this study was to compare the pharmacokinetic disposition of two intravenous dexrazoxane formulations, and… 
2010
2010
Good clinical and cost outcomes using dexrazoxane to treat accidental epirubicin extravasation.
A 75-year-old man diagnosed with lower esophageal adenocarcinoma suffered from epirubicin extravasation during the second cycle… 
2006
2006
A Three-Dimensional Quantitative Structure-Activity Relationship Study of the Inhibition of the ATPase Activity and the Strand Passing Catalytic Activity of Topoisomerase IIα by Substituted Purine…
Based on the topoisomerase IIα catalytic inhibitory activity of a previous hit compound, NSC35866, we screened 40 substituted… 
2000
2000
[Cardiotoxic complications in Wilms' tumour survivors after treatment with anthracyclines].
The aim of the study was an evaluation of circulatory system functions in patients with Wilms' tumour who underwent the multidrug… 
1998
1998
ICRF-187 (dexrazoxan) protects from adriamycin-induced nephrotic syndrome in rats.
BACKGROUND Reactive oxygen species produced during metabolism of adriamycin are purported to play an important role in the… 
1997
1997
Preclinical comparison of bis-diketopiperazine-propane (dexrazoxane) and bis-diketopiperazine-ethane (antimet) on the adriamycin-cardiotoxic effect.
A cardiotoxic effect induced by adriamycin (by repeated i.v. administration to experimental rats in 7-day intervals of… 
Review
1996
Review
1996
A Review of the Modulation of Cisplatin Toxicities by Chemoprotectants
In 1988, Dr. Brian Leyland-Jones questioned “Whither the Modulation of Platinum” in an editorial in the Journal of the National… 
Review
1996
Review
1996
Cardioprotection by dexrazoxane (Cardioxane; ICRF 187): Progress in supportive care
The dose-limiting toxicity of the widely used anticancer agent, doxorubicin, is a destructive, irreversible and progressive… 
1996
1996
Protective effects of cardioxane against anthracycline-induced cardiotoxicity in relapsed acute myeloid leukemias.
The clinical use of anthracyclines and related antitumor agents is limited by their cumulative dose-related cardiac toxicity… 
Review
1991
Review
1991
Cardioxane--ICRF-187 towards anticancer drug specificity through selective toxicity reduction.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)